Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.58 |
| ▸ | GRM5 | P41594 | 11/20 | 0.58 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30308912 | 0.92 | GRM1 (0.64) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL901325 | 0.89 | GRM1 (0.50) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL17837639 | 0.87 | GRM1 (0.57) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL23362181 | 0.87 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL16544582 | 0.87 | GRM5 (0.59) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL29664333 | 0.87 | GRM1 (0.59) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL2878306 | 0.86 | GRM1 (0.60) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL23873484 | 0.86 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL5337565 | 0.86 | GRM1 (0.58) | GRM1GRM5PDK4NAMPTTNK2 | |
| SCHEMBL29826464 | 0.86 | GRM1 (0.60) | GRM1GRM5PDK4NAMPTTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| EP-4242202-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023000834-A1 | BENZIMIDAZOLE OR AZABENZIMIDAZOLE-6-CARBOXYLIC ACID COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| WO-2022111624-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2021018023-A1 | SMALL MOLECULE GLP-1 RECEPTOR MODULATOR | 济南泰达领创医药技术有限公司 | 2021-02-04 | — | — | WO | disclosed |
| EP-2331522-B1 | TETRAHYDROPYRIDINYL AND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHIONOGI & CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHIONOGI & CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| US-8324249-B2 | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324249-B2 | Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHINOGI & CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | SHINOGI & CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2010014257-A2 | TETRAHYDROPYRIDINYL AND DIHYDROPYRROLYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | GRM1 4646/4885GRM5 4725/4885PDK4 562/4885 |
| US-20240246959-A1 | BENZIMIDAZOLE DERIVATIVE AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GLP1R, GIPR, GCGR | GRM1 851/4885GRM5 1465/4885PDK4 680/4885 |
| US-20130150377-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | TRPV1, CACNA1A, CACNA1E | GRM1 428/4885GRM5 265/4885PDK4 2303/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | GRM1 4646/4885GRM5 4725/4885PDK4 562/4885 |
| US-20110136833-A1 | Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof | TRPV1, CACNA1A, CACNA1E | GRM1 428/4885GRM5 265/4885PDK4 2303/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | GRM1 4646/4885GRM5 4725/4885PDK4 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.